- Home
- WSBF vs STRO Comparison
WSBF vs STRO Comparison
Compare WSBF & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- STRO
- Stock Information
- Founded
- WSBF 1921
- STRO 2003
- Country
- WSBF United States
- STRO United States
- Employees
- WSBF N/A
- STRO N/A
- Industry
- WSBF Savings Institutions
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBF Finance
- STRO Health Care
- Exchange
- WSBF Nasdaq
- STRO Nasdaq
- Market Cap
- WSBF 296.4M
- STRO 292.6M
- IPO Year
- WSBF N/A
- STRO 2018
- Fundamental
- Price
- WSBF $14.99
- STRO $2.82
- Analyst Decision
- WSBF
- STRO Strong Buy
- Analyst Count
- WSBF 0
- STRO 7
- Target Price
- WSBF N/A
- STRO $12.14
- AVG Volume (30 Days)
- WSBF 32.5K
- STRO 1.0M
- Earning Date
- WSBF 01-28-2025
- STRO 11-13-2024
- Dividend Yield
- WSBF 4.02%
- STRO N/A
- EPS Growth
- WSBF 40.34
- STRO N/A
- EPS
- WSBF 0.71
- STRO N/A
- Revenue
- WSBF $133,232,000.00
- STRO $160,955,000.00
- Revenue This Year
- WSBF N/A
- STRO N/A
- Revenue Next Year
- WSBF N/A
- STRO N/A
- P/E Ratio
- WSBF $21.31
- STRO N/A
- Revenue Growth
- WSBF N/A
- STRO 230.90
- 52 Week Low
- WSBF $10.60
- STRO $2.45
- 52 Week High
- WSBF $16.86
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- WSBF 46.99
- STRO 43.18
- Support Level
- WSBF $14.75
- STRO $2.66
- Resistance Level
- WSBF $15.25
- STRO $2.86
- Average True Range (ATR)
- WSBF 0.34
- STRO 0.18
- MACD
- WSBF -0.06
- STRO 0.02
- Stochastic Oscillator
- WSBF 23.77
- STRO 86.00
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.